Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kinase inhibitor
Biotech
Racing Takeda, InnoCare reports TYK2 inhibitor win in vitiligo
A phase 2 trial of soficitinib in vitiligo hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.
Nick Paul Taylor
Jul 16, 2026 9:36am
Merck inks Keytruda supply pact to support Exelixis cancer trial
May 19, 2026 9:38am
Incyte vets raise $102M to create better PARP, PI3K drugs
Jan 24, 2024 8:38am
Roche’s breast cancer drug hits primary endpoint in phase 3
Dec 5, 2023 4:12am
BeiGene offers up $1.3B in biobucks for preclinical cancer drug
Nov 21, 2023 7:13am
Roche pays $70M for HER2 breast cancer brain metastases prospect
May 9, 2023 6:30am
